Death-Associated Protein Kinase Promoter Hypermethylation in Normal Human Lymphocytes

Ashok N. Reddy, Wei W. Jiang, Michael Kim, Nicole Benoit, Rodney Taylor, John Clinger, David Sidransky, Joseph A. Califano

Research output: Contribution to journalArticle

44 Scopus citations


A high frequency of death-associated protein kinase (DAPK) promoter hypermethylation has been noted in B-cell malignancies, head and neck cancers, and other solid tumors, and it has been used as a tumor marker in molecular detection strategies. Low levels of DAPK promoter hypermethylation, ranging from 0.003 to 1.181%, were detected in peripheral blood cells from 75 of 143 (52%) normal subjects by quantitative methylation-specific PCR (Q-MSP). In 10 of 10 selected patients, MSP amplification of a portion of the DAPK promoter followed by PCR product sequencing confirmed dense hypermethylation of the CpG island in their peripheral blood cells. Q-MSP analysis of fluorescence-activated cell-sorted peripheral blood cells from three of these patients demonstrated that a significantly greater proportion of B cells (1.074-6.026%) were DAPK hypermethylated than were T cells, monocytes, or neutrophils, which were

Original languageEnglish (US)
Pages (from-to)7694-7698
Number of pages5
JournalCancer Research
Issue number22
Publication statusPublished - Nov 15 2003
Externally publishedYes


ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Reddy, A. N., Jiang, W. W., Kim, M., Benoit, N., Taylor, R., Clinger, J., ... Califano, J. A. (2003). Death-Associated Protein Kinase Promoter Hypermethylation in Normal Human Lymphocytes. Cancer Research, 63(22), 7694-7698.